Pipeline
Intellectual Property Strategy
HOME
>
Pipeline
>
Intellectual Property Strategy
We build an intellectual property strategy that protects our research properly and carries new drug candidates through to research, co-development, licensing and clinical development.
Our intellectual property is not confined to one therapeutic area or one technology. What has been published includes granted patents and patent applications, in Japan and elsewhere, across several fields of research and development, oncology among them.
Our Stance
Inventions, technologies, data and know-how arising from our research and development are protected and managed through a combination of patents, trade marks, know-how and trade secrets, chosen according to the nature of the technology, the stage of development and our business strategy.
In joint research and co-development we distinguish background IP, held by each party before the work begins, from foreground IP, the results that arise from it, and we set out ownership, filing, rights to work the invention, licensing to third parties and publication of results in the agreement.
IP Portfolio
PATENTS
We file and prosecute patents in Japan and abroad on new drug candidates, uses, compositions, manufacturing methods and other research results, according to the nature of the technology and the stage of development. We have published granted patents, PCT international publications and national application publications across several fields of research and development, oncology among them.
TRADE MARKS
Product and service names are registered and managed when required for brand protection and business needs. For registered marks we publish the country or region of registration and the registration number, so far as these can be disclosed.
KNOW-HOW & TRADE SECRETS
Manufacturing conditions, evaluation methods, analytical techniques and other undisclosed technical information are managed as know-how or trade secrets where appropriate, weighed against the disclosure that a patent application entails.
Published IP & Legal Status
Oncology-related Intellectual Property
Oncology is one of several fields in which we work. The cases below are examples of published intellectual property; they do not represent the whole of our research and development or of our patent portfolio.
JP7873525B1
Type
Granted patent
Title
Cancer treatment using extracellular secretion
Country / region
Japan
Legal status
Granted / Active
Proprietor / applicant
General Incorporated Association Advalife Science
WO2026176598A1
Type
PCT publication
Title
Cancer treatment using extracellular secretion
Country / region
International
Legal status
PCT publication
Proprietor / applicant
General Incorporated Association Advalife Science
WO2026177208A1
Type
PCT publication
Title
Cancer treatment using BRMs
Country / region
International
Legal status
PCT publication
Proprietor / applicant
General Incorporated Association Advalife Science
TW202634060A
Type
Published application
Title
Biological response modifiers (BRMs) and their uses
Country / region
Taiwan
Legal status
Pending
Proprietor / applicant
General Incorporated Association Advalife Science
Case details
JP7873525B1
Japan · Granted / Active
Title
Cancer treatment using extracellular secretion
Registered title (Japanese)
細胞外分泌物とアスコルビン酸成分の組合せによる癌処置技術
Subject matter
Cancer treatment technology combining extracellular secretions with an ascorbic acid component
Filing date
20 February 2025
Patent gazette
12 June 2026
Proprietor
General Incorporated Association Advalife Science
WO2026176598A1
PCT publication
Title
Cancer treatment using extracellular secretion
PCT application no.
PCT/JP2025/005920
Filing date
20 February 2025
International publication
27 August 2026
Patent Applicant
General Incorporated Association Advalife Science
WO2026177208A1
PCT publication
Title
Cancer treatment using BRMs
Subject matter
Cancer treatment technology combining BRMs with ascorbic acid
Priority date
20 February 2025
International filing date
20 February 2025
International publication
27 August 2026
Patent Applicant
General Incorporated Association Advalife Science
TW202634060A
Taiwan · Published application / Pending
Title
Biological response modifiers (BRMs) and their uses
Subject matter
Technology relating to BRMs and their uses
Priority date
31 October 2024
Taiwan filing date
31 October 2025
Patent Applicant
General Incorporated Association Advalife Science
Granted patents and patent applications are different in law to international publications and published applications. Neither a PCT international publication nor a national publication of an application is in itself a patent right.
Legal status may change through examination, prosecution, national phase entry and maintenance. This page carries the information that could be verified at the time of publication.
Registered Trademarks
We hold trademark registrations for our organisation name and for names related to our activities, and manage and protect our brands.
商標権者
General Incorporated Association Advalife Science
アドヴァライフ サイエンス／Advalife Science
Registration number
No. 6704270
Country or region
Japan
アドヴァライフ／Advalife
Registration number
No. 6695392
Country or region
Japan
シンクレア銀座クリニック
Registration number
No. 6657105
Country or region
Japan
SINCLAIR
Registration number
No. 6657103
Country or region
Japan
シンクレア
Registration number
No. 6811443
Country or region
Japan
Puerfons
Registration number
第6811443号
Country or region
Japan
アインプロス／ainprose
Registration number
No. 6718312
Country or region
Japan
Trademark Applications
We have filed trademark applications for the following names.
Applicant
General Incorporated Association Advalife Science
SINCLAIR SHINSAIBASHI CLINIC／シンクレア心斎橋クリニック
Application number
No. 2025-078031
Country or region
Japan
NOVARK BIO
Application number
No. 2026-000677
Country or region
Japan
Trademark names are shown in their display form. Registration and application numbers, and the country or region, are shown on the basis of the official registers.
A registered trademark and a pending application are different in legal status. A pending application does not of itself mean that a trademark right exists.
Licensing & Partnering
Licensing and co-development
We welcome discussions about joint research, co-development and licensing in relation to the development assets, technologies and intellectual property we hold and manage.
Indication, territory, field, exclusivity, the rights covered and the division of development, manufacturing and commercialisation are discussed case by case, according to the programme and the legal status of the intellectual property concerned. For details, see Licensing Opportunities.
Discussions begin with the sharing of non-confidential information. Where required, detailed information on intellectual property, non-clinical and clinical data, CMC and development plans is then disclosed in stages, following an NDA or CDA.
Which rights can be licensed, and on what scope, depends on ownership, co-ownership, third-party rights, existing agreements and the status of protection in each country or region. The rights and terms in any particular case are settled through due diligence and the resulting agreement.
PIPELINE
Contact us
Our team will respond to your enquiry.